These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 2968759

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The prognostic significance of ploidy and DNA-heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma.
    Nagel R, al Abadi H.
    Scand J Urol Nephrol Suppl; 1991; 138():83-92. PubMed ID: 1785025
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
    Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct 09; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

  • 9. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul 09; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Jul 09; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U.
    Wien Klin Wochenschr; 1988 Jan 08; 100(1):16-9. PubMed ID: 2964127
    [Abstract] [Full Text] [Related]

  • 16. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V, Nagel R, Al-Abadi H, Schmidt-Gollwitzer M.
    Prostate; 1983 Jan 08; 4(6):553-68. PubMed ID: 6415628
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Jan 08; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 19. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985 Jan 08; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.